Sponsor
Second Affiliated Hospital of Nanchang University
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Second Affiliated Hospital of Nanchang University appears in 39 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
39 shownVebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 ExpressionNCT07655622 · lead sponsor · 2026-07-03
RECRUITINGDouble-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudyNCT07398599 · lead sponsor · 2026-02-15
RECRUITINGSFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLCNCT07131319 · lead sponsor · 2025-04-21
RECRUITINGSuperselective Adrenal Arterial Embolization for Refractory Hypertension: A Proof-of-Concept StudyNCT06568640 · lead sponsor · 2024-08-01
RECRUITINGOlanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLCNCT06554613 · lead sponsor · 2024-07-02
RECRUITINGClinical Efficacy and Safety of Left Bundle Branch Area Pacing Using Quantitative Guidance of Multimodal Data in the Treatment of Heart FailureNCT07814612 · lead sponsor · 2024-03-01
RECRUITINGThe Impact of Semaglutide Compared to Energy Restriction on Type 2 DiabetesNCT07272343 · lead sponsor · 2023-02-10
RECRUITINGClinical Risk Score Prediction for Risk of Dementia Among Late-life Population With DepressionNCT07676851 · lead sponsor · 2006-06-01
RECRUITINGA Cluster-Randomized Controlled TrialNCT07845448 · lead sponsor · 2026-09-10
NOT_YET_RECRUITINGThe Underlying Neural Mechanism of TMS in Improving the Imbalance of "Microbiota-brain-gut Axis" in Alzheimer 's Disease PopulationNCT07346794 · lead sponsor · 2026-04-21
NOT_YET_RECRUITINGAdjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung CancerNCT06773156 · lead sponsor · 2024-11-01
ENROLLING_BY_INVITATIONCSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLCNCT06557096 · lead sponsor · 2024-08-20
NOT_YET_RECRUITINGStudy of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNCT05812534 · lead sponsor · 2023-12-01
UNKNOWNThe Relation Between the Prognosis of Subthalamic Nucleus Deep Brain Stimulation Surgery by Microlesion Effect and Electrode PositionNCT06685510 · lead sponsor · 2023-11-06
ENROLLING_BY_INVITATIONGlycemic Variability, Gut Microbiota, and Prognosis in T2DM With ACSNCT06573060 · lead sponsor · 2023-07-05
UNKNOWNSuperselective Adrenal Arterial Embolization for Bilateral Idiopathic Hyperaldosteronism: A Prospective Cohort StudyNCT05186675 · lead sponsor · 2022-01-01
UNKNOWNCombining Wearable Technology to Crate Internet+Digital Hospital-remote Home Type 2 Diabetes Follow-up Management ModeNCT04973644 · lead sponsor · 2021-08-21
COMPLETEDAlmonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal MetastasisNCT04944069 · lead sponsor · 2021-07-01
UNKNOWNGefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With GefitinibNCT04358562 · lead sponsor · 2020-05-01
UNKNOWNThe Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLCNCT04193007 · lead sponsor · 2019-12-01
UNKNOWNOsimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisNCT04148898 · lead sponsor · 2019-11-01
UNKNOWNPhase I Study of the Combination of Anlotinib With GefitinibNCT03602027 · lead sponsor · 2018-08-01
UNKNOWNOsimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung CancerNCT04425681 · lead sponsor · 2017-10-01
UNKNOWNComprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional SurveyNCT03363360 · lead sponsor · 2016-12-01
UNKNOWNChildren and Adolescent Registry for Diabetes Study in JiangxiNCT03399565 · lead sponsor · 2016-01-18
UNKNOWNFeasibility Study of the Intensive Systolic Blood Pressure ControlNCT02817503 · lead sponsor · 2015-12-01
UNKNOWNDigital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF)NCT07352891 · collaborator · 2026-02-26
RECRUITINGPD-L1 Inhibitor Rechallenge After Immunotherapy-Related Pneumonitis in Patients With Lung CancerNCT07775820 · collaborator · 2025-10-20
RECRUITINGChina Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)NCT04974138 · collaborator · 2024-08-22
RECRUITINGChina Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT GenotypeNCT04974151 · collaborator · 2024-08-22
RECRUITINGAI-Enhanced Optimization of Acute Levodopa Challenge TestNCT06949865 · collaborator · 2024-05-28
RECRUITINGPrognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omicsNCT06001073 · collaborator · 2022-12-05
RECRUITINGSuperselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic HyperaldosteronismNCT07328230 · collaborator · 2022-08-01
RECRUITINGStudy on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPDNCT07665359 · collaborator · 2026-07-01
NOT_YET_RECRUITINGPreemptive TIPS for Gastric Variceal Bleeding in Patients With CirrhosisNCT06122792 · collaborator · 2024-01-01
NOT_YET_RECRUITINGSafety and Effectiveness of Left Bundle Branch Pacing in Patients With Cardiac Dysfunction and AV BlockNCT05553626 · collaborator · 2022-09-01
UNKNOWNH-Type Hypertension Precision Medicine TrialNCT03472508 · collaborator · 2018-03-20
UNKNOWNEfficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma HomocysteineNCT01956786 · collaborator · 2013-09-01
UNKNOWNApplication of Machine Learning Algorithms to Identify Optimal Candidates for Primary Tumor Resection in Patients with Metastatic Non-small Cell Neuroendocrine TumorsNCT06621147 · collaborator · 2000-01-01
COMPLETEDDrugs studied in this sponsor's trials
13 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Second Affiliated Hospital of Nanchang University as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
bevacizumab4
amlodipine besylate2
gefitinib2
osimertinib2
amlodipine1
enalapril1
folic acid1
nivolumab1
bevacizumab RxCUI 253337 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting
4 trials
amlodipine besylate RxCUI 104416 · Lead sponsor in 0 linked trial(s) · 2 currently recruiting
2 trials
gefitinib RxCUI 328134 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
osimertinib RxCUI 1721560 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting
2 trials
amlodipine RxCUI 17767 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
enalapril RxCUI 3827 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
folic acid RxCUI 4511 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
nivolumab RxCUI 1597876 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
olanzapine RxCUI 61381 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
osimertinib 80 MG RxCUI 1721580 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
placebo RxCUI 8375 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
semaglutide RxCUI 1991302 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting
1 trial
spironolactone RxCUI 9997 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting
1 trial
Sponsor roles
lead sponsor26
collaborator13
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.